Succimer
As of the edition of 20 October 2026, Succimer is a small molecule: marketed, first approved in 1991 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Chemet
- First approved
- 30 January 1991 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Serb; 2 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Chemically induced; Digestive system; Inherited and neonatal; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 2 | 0 | 1 | 0 |
| Phase 2 | 2 | 0 | 1 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Recordati Rare Diseases | Acquired holder | 2013 to now |
| Johnson & Johnson | Originator | 1991 to 2013 |